Latest Corporate Restructure News

Arena REIT delivered higher earnings, distributions and asset values in FY2026, but the failure of a major childcare tenant has forced a sharp reset in its near-term outlook. Edge Early Learning accounts for about 14% of rental income and is now in voluntary administration after missing rent.

Alfabs Australia’s FY26 reset preserved free cash flow despite a sharp earnings decline, while Mining growth and debt refinancing form the bridge to a potential dividend restart. The company enters FY27 leaner, but the plan still depends on execution, cash conversion and Phase II debt restructuring.

Lithium Plus Minerals has significantly upgraded its Lei Lithium Project resource and secured a 20-year mining lease, positioning the company for near-term development and commercialisation.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.

Mayfield Childcare’s HY26 results reveal a 6% revenue decline and deepening statutory loss, offset by operational improvements and strategic restructuring.

Locate Technologies (NZX: LOC) posted a NZD 3.53 million loss for FY2026 despite 7.8% revenue growth, facing refinancing uncertainty on a major debt facility due in November.

Encounter Resources has launched a strategic review of its copper assets across Western Australia and the Northern Territory, aiming to accelerate project development amid promising drilling results at its Yeneena Copper Project and other key sites.

Tarrina Resources (ASX:TR8) posted a $3.63 million loss for FY2026 as it ramped up exploration at its newly acquired gold and base metal projects following a $5 million capital raise and ASX relisting.

Arena REIT faces a rent payment default from key tenant Edge Early Learning, representing 14% of rental income, prompting default notices and a delay in FY2026 financial results.

IperionX plans to relocate its parent company to Texas and list directly on Nasdaq, aligning its corporate structure with its US operations. The appointment of manufacturing veteran Michael J. Loparco aims to bolster the company’s industrial scale-up.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Prestal Holdings Limited (ASX: PTL) has voluntarily suspended trading in its shares pending disclosure of a significant transaction. Details remain under wraps as the company complies with ASX requirements.